Health
Pfizer, BioNTech Shares Ripe for a Bumpy Ride Ahead of Key Panel – BloombergQuint
Pfizer, BioNTech Shares Ripe for a Bumpy Ride Ahead of Key Panel
(Bloomberg) — Its been a wild ride for Pfizer Inc. shares as the S&P 500 heavyweight got caught up in the vaccine-stock euphoria. A key panel next week could mean even more volatility.
A Food and Drug Administration advisory committee meeting scheduled for Dec. 10 is believed to be a means for the agency to assure the public about Covid-19 vaccine safety, and a U.S. emergency use authorization could follow within days.
Pfizer shares have gained about 20% since late October even after a dip on Thursday,…
-
Noosa News17 hours agoOnly person charged over Spear Creek murders admits he lied to police
-
Noosa News18 hours agoAllegedly armed man who sparked hours-long lockdown of Brisbane City Botanic Gardens in custody
-
Business24 hours agoLynas Rare Earths shares storm higher to 14-year peak: Buy, hold, or sell?
-
Business20 hours agoGold price races towards US$4,200 on Tuesday